CLOs on the Move

Advanced Reproductive Care

www.arcfertility.com

 
Advanced Reproductive Care is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Excelin Health

Excelin Health owns and operates several quality home health agencies across the country.

Express Medical Transporters

Express Medical Transporters is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glendive Medical Center

Glendive Medical Center Inc. is a Glendive, MT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

InterWell Health

Interwell Health is a kidney care management company that partners with physicians on its mission to reimagine healthcare – with the expertise, compassion, and vision to set the standard for the industry and help patients live their best lives. The company is differentiated by its ability to deliver improved clinical outcomes and better quality of life for patients, reduce the total cost of care for payer partners, and provide the resources physicians need to thrive in a value-based world – all at scale.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.